Dow Jumps Over 250 Points; US Initial Jobless Claims Increase

BY Benzinga | ECONOMIC | 01/08/26 12:33 PM EST

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 250 points on Thursday.

The Dow traded up 0.54% to 49,261.60 while the NASDAQ declined 0.62% to 23,437.73. The S&P 500 also fell, dropping, 0.05% to 6,917.76.

Check This Out: Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Leading and Lagging Sectors

Industrials shares gained by 1.4% on Thursday.

In trading on Thursday, information technology stocks dipped by 1.4%.

Top Headline

U.S. initial jobless claims increased by 8,000 from the previous week to 208,000 in the week ending Jan. 3, compared to market expectations of 210,000.

Equities Trading UP
           

  • Flyexclusive Inc (FLYX) shares shot up 126% to $7.10 after the company was named an authorized Starlink Aviation dealer.
  • Shares of Enliven Therapeutics Inc (ELVN) got a boost, surging 54% to $23.81 after the company announced initial data from the ongoing Phase 1b ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia that is relapsed, refractory or intolerant to available tyrosine kinase inhibitors.
  • MoonLake Immunotherapeutics (MLTX) shares were also up, gaining 29% to $14.54 after the company said FDA feedback confirmed it may establish substantial evidence of effectiveness for hidradenitis suppurativa without additional clinical trials.

Equities Trading DOWN

  • Immuneering Corp (IMRX) shares dropped 39% to $5.10. The company announced updated overall survival and safety data from its ongoing Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, with over 13 months median follow up time.
  • Shares of Acrivon Therapeutics Inc (ACRV) were down 31% to $2.05 after the company announced ACR-368 Phase 2b endometrial cancer clinical data with EU expansion to accelerate enrollment, initial ACR-2316 clinical data, and ACR-6840, its next AP3-enabled development candidate, targeting CDK11.
  • CorMedix Inc (CRMD) was down, falling 23% to $8.00. The company announced preliminary fourth-quarter and FY25 revenue results.

Commodities

In commodity news, oil traded up 1.8% to $56.98 while gold traded down 0.1% at $4,456.70.

Silver traded down 3.6% to $74.820 on Thursday, while copper fell 1.7% to $5.7600.

Euro zone

European shares were mixed today. The eurozone's STOXX 600 slipped 0.27%, while Spain's IBEX 35 Index rose 0.27%. London's FTSE 100 declined 0.06%, Germany's DAX fell 0.08% and France's CAC 40 rose 0.06% during the session.

Asia Pacific Markets

Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 1.63%, Hong Kong's Hang Seng Index declining 1.17%, China's Shanghai Composite slipping 0.07% and India's BSE Sensex falling 0.92%.

Economics

  • U.S. initial jobless claims increased by 8,000 from the previous week to 208,000 in the week ending Jan. 3, compared to market expectations of 210,000.
  • Nonfarm business sector labor productivity rose by 4.9% in the third quarter, following a revised 4.1% gain in the prior quarter.
  • Unit labor costs in the nonfarm business sector fell by 1.9% in the third quarter, compared to market expectations of a 1.0% growth.
  • The US trade deficit shrank to $29.4 billion in October, recording the smallest gap since June 2009, versus a revised $48.1 billion gap in September and compared to market estimates of a $58.1 billion gap.

Now Read This:

  • How To Earn $500 A Month From JPMorgan Stock Ahead Of Q4 Earnings

Photo via Shutterstock

In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.

Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.

fir_news_article